Project Grant R01HL177625
Award Date
1/15/25
Completion Date
11/30/28
Dollars Obligated
$617K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), will support research to characterize the role of lung stromal factors in modulating the inflammatory response and tissue-resident lymphocyte accumulation in asthmatic airways. The $636,843 award to the Regents of the University of California, San Francisco will utilize novel genetic tools, human organoid platforms, and a proprietary...
This federal Project Grant award of $387,116 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) aims to define the neural mechanisms triggered by house dust mite (HDM) exposure that lead to the development of airway hyperreactivity (AHR) in asthma. The research seeks to identify the specific nerve subtypes and signaling pathways involved in HDM-induced AHR, in order to develop targeted therapies. Specifically, the study...
This $613,934 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, supports research at North Dakota State University (NDSU) to investigate the role of the aryl hydrocarbon receptor (AhR) signaling in airway smooth muscle and its effects on inflammation, hyperresponsiveness, and remodeling in asthma. The key research objectives are to: 1) determine the mechanisms of AhR expression and regulation in human...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,016,357 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Mayo Clinic in Rochester, MN to study the role of transmembrane protein 178 (TMEM178) in asthma pathogenesis. The research aims to characterize how TMEM178-mediated inhibition of calcium responses in bronchial epithelial cells is disrupted in asthma, understand the impact of genetic TMEM178 loss on lung inflammation and airway remodeling in mouse models,...
This $347,608 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of a novel, oral, once-daily immunoregulatory therapeutic for the treatment of asthma by Biotherapeutics, Inc., an emerging biotechnology company. The goal is to characterize the therapeutic efficacy and administration route of the drug candidate in mouse models of asthma, and determine its translational potential...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to investigate the mechanism by which early-life respiratory syncytial virus (RSV) infection predisposes children to developing asthma later in life. The $565,834 award will fund a 1-year study at the University of Michigan to define whether early-life RSV infection generates long-lasting changes in the lung epithelium that...
This federal Project Grant award of $249,000.00 from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop methodologies to reveal the role of the blood microbiome in the gut-lung axis for asthma pathogenesis. The award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, will fund the creation of a strain-resolved computational pipeline for reduced metagenomic...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to integrate multi-omics data and understand the heterogeneity and endotypes of asthma. The $177,403 award, effective September 1, 2024 through August 31, 2029, will enable the Brigham & Women's Hospital Inc. to analyze the interplay between genetic, epigenetic, and metabolomic factors in asthma...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $355,935 to Biotherapeutics, Inc., a biotechnology company located in Blacksburg, Virginia. The grant funding supports the development of a novel, oral immunoregulatory therapeutic for treating asthma. The key objectives are to characterize the therapeutic efficacy and optimal route of administration in mouse models of asthma, and...
This $1,147,992 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to advance precision medicine for acute respiratory distress syndrome (ARDS) and sepsis. The award aims to address key unanswered questions about the functional immune response and pathogen drivers underlying distinct "hyperinflammatory" and "hypoinflammatory" phenotypes observed in these critical...